Newsletter Archives - Page 3 of 3 - Hamlet BioPharma

Newsletter

Nov

12

2025

PRESSRELEASE – Lund 12 november, 2025 – Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas

Hamlet Biopharma

|

Newsletter, Press releases

Förslag ny styrelsesammansättning och ny ordförande Inför ordinarie årsstämma i Hamlet BioPharma föreslår större ägare omval av Catharina Svanborg, Ma...

Read more

Nov

10

2025

PRESS RELEASE – Lund, November 10th, 2025 – Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

Hamlet Biopharma

|

Newsletter, Press releases

HAMLET BioPharma, a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received writt...

Read more

Nov

05

2025

Newsletter – Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections

Hamlet Biopharma

|

One of the most comprehensive studies ever conducted in childhood urinary tract infection shows that a chaotic immune response causes symptoms and dam...

Read more

Nov

05

2025

Nyhetsbrev – Klinisk studie på spädbarn bekräftar Hamlet BioPharmas strategi för icke-antibiotisk behandling av infektioner

Hamlet Biopharma

|

En av de mest omfattande studierna någonsin av urinvägsinfektion hos barn visar att ett kaotisk immunsvar orsakar symptom och vävnadsskada – int...

Read more

Dec

07

2023

Newsletter – Continuing development of brain tumor therapy

Hamlet Biopharma

|

The brain and spinal cord form the central nervous system, where vital functions are controlled. Brain tumors that disturb those functions may be...

Read more

Nov

02

2023

Newsletter – Bladder cancer

Hamlet Biopharma

|

...

Read more

Oct

16

2023

Newsletter – Strong anti-tumor effects detected in Alpha1H patients

Hamlet Biopharma

|

...

Read more

Oct

03

2023

Newsletter – FDA approval

Hamlet Biopharma

|

...

Read more

1
2
3

Recent posts

Pressrelease – Lund, April 23, 2026 – Monthly investor meeting on the 29th of April, 2026

April 23, 2026

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

March 30, 2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

March 24, 2026

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

March 17, 2026

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

© 2026

Hamlet BioPharma.